Optimizing Treatment Strategies in the Management
of Rheumatoid Arthritis: Novel Therapies
for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 2, 2018 to April 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Lilly USA LLC

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, treatment is to control the pain, during flair ups especially, and to prevent joint damage. Rheumatoid arthritis varies greatly from patient to patient, and with each patient it varies over time. Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare professionals. An understanding of the pathogenesis of RA and the role of different treatment approaches, including current and emerging therapies, will assist healthcare providers in determining the best course of therapeutic management for optimal long-term patient outcomes. Fortunately, new treatments, to include non-biologic DMARDS, have shown improved efficacy and safety and should be implemented into the treatment paradigm to ultimately improve patient outcomes.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast the efficacy and safety of current and emerging biologic therapies in the management of Rheumatoid Arthritis (RA) for achieving individualized treatment goals and outcomes

  • Examine the latest data available on the role of anti-citrullinated protein antibodies (ACPAs), among other RA biomarkers, as part of the pathophysiology of RA

  • Analyze available tools for monitoring rheumatoid arthritis disease activity and progression and their utility in optimizing therapy

  • Tailor treatment regimens for moderate-to-severely active RA based on repeated assessment of RA biomarkers, disease activity, functional status, treatment response, and other patient-specific risks

  • Explore treat-to-target strategies based on objective measures of RA activity and comprehensive evaluations of localized and systemic disease manifestations

  • Evaluate the direct and indirect costs of RA and develop strategies to reduce the cost burden on patients and society

Faculty: Maureen McMahon, MD, MS
Associate Clinical Professor
UCLA David Geffen School of Medicine
Division of Rheumatology


Dr. McMahon has no relevant financial relationships to disclose. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Lilly USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue